Skip to content
  • Home
  • Allergen Immunotherapy
  • Knowledge Hub
    • Insights and Perspectives
    • Terminology
  • About Us
  • Contact

Latest News & Articles

< Back To Newsroom

  • Investment Opportunities

    Investor Insights: Why the Poison Ivy Vaccine is a Smart Bet

    August 11, 2026

1122 N. High Street,
Millville, NJ 08332-2529

Contact Us >

BOME’s immunotherapy is currently not FDA approved. We are in the process of further product refinement and hope to conduct clinical trials in the near future.

Page load link
Go to Top